Solveigh is pleased to announce that Wolters Kluwer has successful entered into a joined venture with China Drug Information Provider Medicom. The deal allows Wolters Kluwer to deliver clinical decision support to doctors in China as the country prepares for significant changes to its healthcare system and to expand its market-leading Clinical Decision Support (CDS) and drug information business into the rapidly growing China market and creates a needed drug information infrastructure in China.
“The clinical decision support market in China is at a critical juncture, similar to what we saw in the U.S. market many years ago,” said Arvind Subramanian, President and CEO, Wolters Kluwer Health Clinical Solutions. “Our agreement with Medicom gives Wolters Kluwer Health a strong entry point in China and creates a solid foundation for us to introduce more advanced CDS products and solutions that will give healthcare professionals in China unparalleled access to evidence-based medicine for the advancement of healthcare.”
Medicom, located in the city of Chengdu in the Sichuan Province, has a strong footprint in the China healthcare market, providing drug information and services. Its products and services are highly complementary to those of Wolters Kluwer Health’s Clinical Solutions business, which offers healthcare professionals fast access to evidence-based medical information that helps clinicians effectively manage patient care on a daily basis. The combined offering creates a robust library of clinical content not previously available in China that physicians can access at the point of learning as well as at the point of care with patients.
The announcement comes as the Chinese government is focused on healthcare reform to conform standards of care and an increasing number of doctors in China prepare to pursue graduate school degrees.
“Our joint venture with Wolters Kluwer Health is a strategic fit for Medicom as we continue to deliver on our mission of providing the most reliable and accurate clinical and drug information for doctors, pharmacists and hospitals,” said Lai Qi, CEO of Medicom. “This partnership will also provide Medicom access to a more comprehensive set of products and services to support China’s healthcare reform initiatives of improving productivity and quality of care.
Ernst Jan Kruis, Founder and CEO at Solveigh commented on the transaction, “The joint venture between Wolters Kluwer and Medicom is an excellent example of 2 partners committed and determined to work through all the issues that cross border deal making requires making a transaction work. We have seen both parties spending relentless effort and time to build understanding and based on that create the best possible structure to further develop business in the market both parties are in. It has been a great pleasure to work on this project with a true team spirit that made us all work in a seamless way.”
Solveigh served as the exclusive advisor to Wolters Kluwer Health.
Category: Joint Venture
Back to the news overview
Wolters Kluwer Health
Ernst Jan Kruis
Solveigh is pleased to announce that EZ-Blocker ® has been acquired by Teleflex Incorporated, listed at the New York Stock Exchange.
Solveigh is pleased to announce that we originated and developed the successfull completion of a joint venture between KEMA and the number 1 energy consulting company in China, Sinopower.
Solveigh is pleased to announce that the management buy out of Hatenboer Water and Hatenboer Neptunus has been completed. Solveigh has arranged and structured the MBO and has advised both the owner and the management team.
Solveigh | T +31 10 238 18 00 | E email@example.com | Westersingel 106 | 3015 LD | Rotterdam
Solveigh | T +852 3695 5001 | Unit 3604A | 36/F Tower 2 Lippo Centre | 89 Queensway | Hong Kong